Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2006

View Archived Issues

Human opiorphin potentiates analgesic effects of enkephalins by inhibiting their degradation

Calpain inhibitor delays disease severity and progression in a mouse model of multiple sclerosis

SF-1126 shows activity against multiple myeloma in preclinical studies

Aurora kinase inhibitor AZD-1152 blocks engraftment of AML tumors in vivo

NVP-TAE226 active against multiple myeloma in preclinical studies

YM-150: favorable biochemical and pharmacological profile reported

Targeting ALK with TAE-684 shows benefit in murine models of lymphoma

Fibrin Patch begins clinical studies

Allon cleared to begin phase II study of AL-108 in mild cognitive impairment

BioCancell advances development of BC-819 for metastatic liver cancer

NB-S101 studied in phase II trial for osteoporosis

Cell Therapeutics to close PIONEER study of Xyotax, new trial planned

V-24343 begins phase I trial for obesity and type 2 diabetes

elbion merges with 4AZA Bioscience

Actelion-1 enters phase III for pulmonary hypertension

GSK to acquire Domantis

Dynavax studies TLR9 agonist with chemotherapy for metastatic colorectal cancer

New agents for urinary incontinence emerge from Astellas Pharma R&D

SLV-319 begins phase IIb study for obesity

Encysive cleared to resume clinical studies with TBC-3711

Recent patents report novel analgesic agents

ReGen explores effects of zolpidem in people with brain damage

DIAS-2 stroke study of desmoteplase completes enrollment

TRO-19622 successfully completes phase Ib studies

Clinical hold lifted on MEM-3454

Recent patents disclose new therapeutic agents for anxiety, depression, etc.

Pafuramidine studied in phase II trial for prevention of malaria infection

Cintredekin besudotox not superior to Gliadel Wafer in phase III trial

1-TDC to begin pre-IND studies

New Rebif formulation studied in phase III

Idraparinux shows encouraging results in patients at high risk of thromboembolism

Xelox meets primary endpoint in phase III advanced colorectal cancer study

Phase III trials of alfimeprase in PAO and catheter occlusion fail to meet endpoints

Tasigna achieves impressive response rates in Glivec-resistant Ph+ CML patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...